AR079712A1 - Composiciones inmunogenicas; kit y vacuna - Google Patents
Composiciones inmunogenicas; kit y vacunaInfo
- Publication number
- AR079712A1 AR079712A1 ARP100104897A ARP100104897A AR079712A1 AR 079712 A1 AR079712 A1 AR 079712A1 AR P100104897 A ARP100104897 A AR P100104897A AR P100104897 A ARP100104897 A AR P100104897A AR 079712 A1 AR079712 A1 AR 079712A1
- Authority
- AR
- Argentina
- Prior art keywords
- composition
- pneumoniae
- isolated
- immunogenic
- polypeptide
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 13
- 230000002163 immunogen Effects 0.000 title abstract 8
- 229960005486 vaccine Drugs 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 8
- 229920001184 polypeptide Polymers 0.000 abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 7
- 239000002671 adjuvant Substances 0.000 abstract 4
- 239000000839 emulsion Substances 0.000 abstract 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 abstract 2
- 239000002736 nonionic surfactant Substances 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 101710183389 Pneumolysin Proteins 0.000 abstract 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 abstract 1
- 208000037062 Polyps Diseases 0.000 abstract 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 abstract 1
- 150000005215 alkyl ethers Chemical class 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003125 aqueous solvent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 229920002704 polyhistidine Polymers 0.000 abstract 1
- -1 polyoxyethylene Polymers 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 229940031439 squalene Drugs 0.000 abstract 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28923609P | 2009-12-22 | 2009-12-22 | |
| US32566010P | 2010-04-19 | 2010-04-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR079712A1 true AR079712A1 (es) | 2012-02-15 |
Family
ID=44194860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100104897A AR079712A1 (es) | 2009-12-22 | 2010-12-22 | Composiciones inmunogenicas; kit y vacuna |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20130183350A1 (enExample) |
| EP (1) | EP2515938A4 (enExample) |
| JP (2) | JP5894083B2 (enExample) |
| KR (1) | KR20120107121A (enExample) |
| CN (1) | CN102802664B (enExample) |
| AR (1) | AR079712A1 (enExample) |
| AU (1) | AU2010335970B2 (enExample) |
| BR (1) | BR112012018343A2 (enExample) |
| CA (1) | CA2783955A1 (enExample) |
| IL (2) | IL220576B (enExample) |
| WO (1) | WO2011075823A1 (enExample) |
| ZA (1) | ZA201204628B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2784447A1 (en) | 2009-12-22 | 2011-06-30 | Sanofi Pasteur Limited | Adjuvanted immunogenic compositions and related methods |
| CA2819758A1 (en) | 2010-12-03 | 2012-06-07 | Sanofi Pasteur Limited | Composition for immunization against streptococcus pneumoniae |
| BR112013029514A2 (pt) | 2011-05-17 | 2019-09-24 | Glaxosmithkline Biologicals Sa | composição imunogênica, vacina, e, método de tratar ou impedir uma doença |
| GB201218660D0 (en) | 2012-10-17 | 2012-11-28 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| CN104853768B (zh) * | 2012-10-17 | 2019-04-19 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合物 |
| CA2894903A1 (en) * | 2012-12-14 | 2014-06-19 | Sanofi Pasteur, Ltd. | Methods for assessing immunogenicity |
| EP3116537A4 (en) * | 2014-03-10 | 2017-09-13 | Sanofi Pasteur Limited | Immunogenic compositions |
| KR101688960B1 (ko) * | 2014-06-11 | 2016-12-23 | 전남대학교산학협력단 | 스쿠티카충 백신 조성물 |
| JP2018502927A (ja) * | 2015-01-27 | 2018-02-01 | スリーエム イノベイティブ プロパティズ カンパニー | マイクロニードルワクチンパッチ用ミョウバン含有コーティング製剤 |
| GB2556002B (en) * | 2015-07-07 | 2020-12-16 | Bluewillow Biologics Inc | Methods and compositions for nanoemulsion vaccine formulations |
| EP3736574A1 (en) * | 2019-05-07 | 2020-11-11 | Atlas Antibodies AB | A formulation comprising an isotope labeled fusion polypeptide |
| WO2023034932A1 (en) * | 2021-09-02 | 2023-03-09 | Vaxcyte, Inc. | Stabilization of adjuvanted vaccine compositions and their use |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUT58804A (en) * | 1988-12-16 | 1992-03-30 | James Cleland Paton | Process for producing pneumolysine mutants and pneumococcus vaccines |
| US6800744B1 (en) * | 1997-07-02 | 2004-10-05 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
| DK1140157T3 (da) * | 1998-12-21 | 2009-06-08 | Medimmune Inc | Streptococcus pneumoniae-proteiner og immunogene fragmenter til vacciner |
| GB0022742D0 (en) * | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
| GB0213622D0 (en) * | 2002-06-13 | 2002-07-24 | Glaxosmithkline Biolog Sa | Vaccine Corporation |
| GB0410220D0 (en) * | 2004-05-07 | 2004-06-09 | Kirkham Lea Ann | Mutant pneumolysin proteins |
| EP1863529A1 (en) * | 2005-03-23 | 2007-12-12 | GlaxoSmithKline Biologicals S.A. | Novel composition |
| TWI457133B (zh) * | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| AU2007285775B2 (en) * | 2006-08-17 | 2011-03-03 | Sanofi Pasteur Ltd. | Immunogenic PcpA polypeptides and uses thereof |
| AU2008280799B2 (en) | 2007-07-23 | 2013-07-11 | Sanofi Pasteur Limited | Immunogenic polypeptides and monoclonal antibodies |
| AU2009208299B2 (en) * | 2008-02-01 | 2015-01-22 | Sanofi Pasteur Limited | Assay for diagnosing streptococcus pneumoniae |
| BRPI0923649A2 (pt) * | 2008-12-24 | 2016-01-19 | Netherlands Vaccine Inst | polipeptídeos de pneumolisina (ply) de streptococcus pneumoniae modificados. |
-
2010
- 2010-12-20 US US13/515,093 patent/US20130183350A1/en not_active Abandoned
- 2010-12-20 WO PCT/CA2010/001977 patent/WO2011075823A1/en not_active Ceased
- 2010-12-20 CA CA2783955A patent/CA2783955A1/en not_active Abandoned
- 2010-12-20 BR BR112012018343A patent/BR112012018343A2/pt not_active IP Right Cessation
- 2010-12-20 JP JP2012545030A patent/JP5894083B2/ja not_active Expired - Fee Related
- 2010-12-20 CN CN201080064532.1A patent/CN102802664B/zh not_active Expired - Fee Related
- 2010-12-20 EP EP10838456.1A patent/EP2515938A4/en not_active Withdrawn
- 2010-12-20 KR KR1020127019061A patent/KR20120107121A/ko not_active Abandoned
- 2010-12-20 AU AU2010335970A patent/AU2010335970B2/en not_active Ceased
- 2010-12-22 AR ARP100104897A patent/AR079712A1/es unknown
-
2012
- 2012-06-21 ZA ZA2012/04628A patent/ZA201204628B/en unknown
- 2012-06-21 IL IL220576A patent/IL220576B/en not_active IP Right Cessation
-
2015
- 2015-11-15 IL IL242592A patent/IL242592A/en not_active IP Right Cessation
- 2015-12-25 JP JP2015254259A patent/JP2016104776A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010335970B2 (en) | 2016-11-03 |
| CN102802664B (zh) | 2017-04-05 |
| IL242592A (en) | 2017-10-31 |
| BR112012018343A2 (pt) | 2017-06-27 |
| US20130183350A1 (en) | 2013-07-18 |
| KR20120107121A (ko) | 2012-09-28 |
| IL220576B (en) | 2018-03-29 |
| EP2515938A4 (en) | 2013-08-28 |
| JP2013515015A (ja) | 2013-05-02 |
| EP2515938A1 (en) | 2012-10-31 |
| WO2011075823A1 (en) | 2011-06-30 |
| AU2010335970A1 (en) | 2012-07-05 |
| CN102802664A (zh) | 2012-11-28 |
| JP2016104776A (ja) | 2016-06-09 |
| JP5894083B2 (ja) | 2016-03-23 |
| ZA201204628B (en) | 2013-02-27 |
| CA2783955A1 (en) | 2011-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR079712A1 (es) | Composiciones inmunogenicas; kit y vacuna | |
| AR054822A1 (es) | Emulsion inmuno adyuvante | |
| PE20250020A1 (es) | Composicion inmunogenica contra la influenza | |
| PE20161560A1 (es) | Vacuna de pcsk9 | |
| PE20080428A1 (es) | Vacunas para la malaria | |
| MX2017014127A (es) | Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos. | |
| MX359954B (es) | Ácido nucleico que comprende o codifica para un asa troncal de histona y una secuencia poly (a) o una señal de poliadenilación para aumentar la expresión de un antígeno patogénico codificado. | |
| CL2016002513A1 (es) | Método para preparar amg 416 | |
| HRP20180282T1 (hr) | Imunoterapija na bazi indoleamin 2, 3-dioksigenaze | |
| MX2017011796A (es) | Lo nuevo complejo que comprende un peptido de penetracion celular, una molecula cargo y un agonista peptidico de tlr. | |
| JP2017511328A5 (enExample) | ||
| WO2006068663A3 (en) | Vaccine compositions for treating coronavirus infection | |
| MX358725B (es) | Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden. | |
| CO5700788A2 (es) | Composiciones y metodos para inmunoterapia especifica de wt1 | |
| AR086078A1 (es) | Proteinas de fusion y vacunas de combinacion | |
| ECSP024257A (es) | Proteinas antigenas del virus de la enfermedad de la mancha blanca en el camaron y usos de las mismas | |
| MX2019005137A (es) | Vacuna contra parvovirus porcino. | |
| AR079706A1 (es) | Composiciones, metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis y uso | |
| BRPI0815578B8 (pt) | Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer) | |
| ES2195169T3 (es) | Vacunas contra calmidias y composiciones inmunogenicas que contienen un antigeno de membrana externa y metodos para su preparacion. | |
| AR109538A1 (es) | Vacuna contra la gripe porcina | |
| CO2019000214A2 (es) | Vacuna contra virus de bronquitis infecciosa | |
| CO2018010874A2 (es) | Vacuna de virus de zika atenuado vivo | |
| US20210187096A1 (en) | Universal vaccine for viral diseases | |
| AR071741A1 (es) | Vacunas contra la malaria |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |